Shots:

• The FDA’s approval is based on P-III study assessing the BOTOX in 300+ pediatric patients aged 2-17yrs. being treated for lower limb spasticity. The study included patients with cerebral palsy- but the approved indication excludes lower limb spasticity caused by cerebral palsy due to marketing exclusivity by another company
•  The approval marks the 11^th BOTOX therapeutic indication and comes 30yrs. after the first indications were approved and recently has been approved for pediatric upper limb spasticity in H1’2019
• BOTOX is a neurotoxin therapy injected in the muscles to treat increased muscle stiffness & eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm)

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Business Insider